Intra-therapeutic dosimetry of [(177)Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome

INTRODUCTION: While [(177)Lu]Lu-PSMA radioligand therapy is currently only applied in end-stage metastatic castrate-resistant prostate cancer (mCRPC) patients, also low-volume hormone-sensitive metastatic prostate cancer (mHSPC) patients can benefit from it. However, there are toxicity concerns rela...

Descripción completa

Detalles Bibliográficos
Autores principales: Peters, Steffie M. B., Privé, Bastiaan M., de Bakker, Maarten, de Lange, Frank, Jentzen, Walter, Eek, Annemarie, Muselaers, Constantijn H. J., Mehra, Niven, Witjes, J. Alfred, Gotthardt, Martin, Nagarajah, James, Konijnenberg, Mark W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803803/
https://www.ncbi.nlm.nih.gov/pubmed/34218300
http://dx.doi.org/10.1007/s00259-021-05471-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803803/
https://www.ncbi.nlm.nih.gov/pubmed/34218300
http://dx.doi.org/10.1007/s00259-021-05471-4

Ejemplares similares